Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis

Clinical and Vaccine Immunology

Volumn 20, Issue 11, 2013, Pages 1743-1751

  Wang, Maowei ^a   Yue, Yan ^a   Dong, Chunsheng ^a   Li, Xiaoyun ^a   Xu, Wei ^a   Xiong, Sidong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; DNA VACCINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN A;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; DENDRITIC CELL; DISEASE SEVERITY; FLOW CYTOMETRY; HEART MUSCLE INJURY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS LOAD; VIRUS MYOCARDITIS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHITOSAN; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; FECES; HMGB1 PROTEIN; IMMUNOGLOBULIN A, SECRETORY; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VIRAL VACCINES;

EID: 84886741121     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00466-13     Document Type: Article

References (56)

1. Calabrese F, Rigo E, Milanesi O, Boffa GM, Angelini A, Valente M, Thiene G. 2002. Molecular diagnosis of myocarditis and dilated cardiomyopathy in children: clinicopathologic features and prognostic implications. Diagn. Mol. Pathol. 11:212-221.
2. Godeny EK, Gauntt CJ. 1986. Involvement of natural killer cells in coxsackievirus B3-induced murine myocarditis. J. Immunol. 137:1695-1702.
3. Leonard EG. 2004. Viral myocarditis. Pediatr. Infect. Dis. J. 23:665-666.
4. Martino TA, Liu P, Sole MJ. 1994. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 74:182-188.
5. Kandolf R, Klingel K, Zell R, Selinka HC, Raab U, Schneider-Brachert W, Bultmann B. 1993. Molecular pathogenesis of enterovirus-induced myocarditis: virus persistence and chronic inflammation. Intervirology 35:140-151.
6. Gangaplara A, Massilamany C, Brown DM, Delhon G, Pattnaik AK, Chapman N, Rose N, Steffen D, Reddy J. 2012. Coxsackievirus B3 infection leads to the generation of cardiac myosin heavy chain-α-reactive CD4 T cells in A/J mice. Clin. Immunol. 144:237-249.
7. Fairweather D, Stafford KA, Sung YK. 2012. Update on coxsackievirus B3 myocarditis. Curr. Opin. Rheumatol. 24:401-407.
8. Zhang L, Parham NJ, Zhang F, Aasa-Chapman M, Gould EA, Zhang H. 2012. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis. Vaccine 30:2301-2308.
9. Henke A, Jarasch N, Martin U, Wegert J, Wildner A, Zell R, Wutzler P. 2008. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease. Int. J. Med. Microbiol. 298:127-134.
10. Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S. 2004. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22:3603-3612.
11. See DM, Tilles JG. 1994. Efficacy of a polyvalent inactivated-virus vaccine in protecting mice from infection with clinical strains of group B coxsackieviruses. Scand. J. Infect. Dis. 26:739-747.
12. Chapman NM, Ragland A, Leser JS, Hofling K, Willian S, Semler BL, Tracy S. 2000. A group B coxsackievirus/poliovirus 5′ nontranslated region chimera can act as an attenuated vaccine strain in mice. J. Virol. 74:4047-4056.
13. Fohlman J, Ilback NG, Friman G, Morein B. 1990. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 8:381-384.
14. Kim JY, Jeon ES, Lim BK, Kim SM, Chung SK, Kim JM, Park SI, Jo I, Nam JH. 2005. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 23:1672-1679.
15. Goodwin GH, Sanders C, Johns EW. 1973. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem. 38:14-19.
16. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251.
17. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. 2006. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174-179.
18. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. 2002. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62:4805-4811.
19. Sundberg E, Fasth AE, Palmblad K, Harris HE, Andersson U. 2009. High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology 214:303-309.
20. Bianchi ME, Manfredi AA. 2007. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220:35-46.
21. Ministry of Health. 1998. Guide for the care and use of medical laboratory animals. Ministry of Health, Beijing, People's Republic of China.
22. Yue Y, Xu W, Xiong S. 2012. Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant. DNA Cell Biol. 31:479-488.
23. Yue Y, Xu W, Hu L, Jiang Z, Xiong S. 2009. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle. Virology 386:438-447.
24. Jiang Z, Xu W, Li K, Yue Y, Xu L, Ye F, Xiong S. 2008. Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hy-drodynamics-based interleukin-4 gene transfer. J. Gene Med. 10:918-929.
25. Dlugonska H, Grzybowski M. 2012. Mucosal vaccination: an old but still vital strategy. Ann. Parasitol. 58:1-8.
26. Sabirov A, Metzger DW. 2008. Mouse models for the study of mucosal vaccination against otitis media. Vaccine 26:1501-1524.
27. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. 2001. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52:139-144.
28. Goldmann K, Ensminger SM, Spriewald BM. 2012. Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance. Clin. Vaccine Immunol. 19:1758-1764.
29. Jiang L, Qian F, He X, Wang F, Ren D, He Y, Li K, Sun S, Yin C. 2007. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice. J. Gene Med. 9:253-264.
30. Porporatto C, Bianco ID, Correa SG. 2005. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukoc. Biol. 78:62-69.
31. Guzman-Morales J, Ariganello MB, Hammami I, Thibault M, Jolicoeur M, Hoemann CD. 2011. Biodegradable chitosan particles induce chemokine release and negligible arginase-1 activity compared to IL-4 in murine bone marrow-derived macrophages. Biochem. Biophys. Res. Commun. 405:538-544.
32. Baek KS, Won EK, Choung SY. 2007. Effects of chitosan on serum cytokine levels in elderly subjects. Arch. Pharm. Res. 30:1550-1557.
33. Slutter B, Bal SM, Que I, Kaijzel E, Lowik C, Bouwstra J, Jiskoot W. 2010. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? Mol. Pharm. 7:2207-2215.
34. Premaletha K, Licy CD, Jose S, Saraladevi A, Shirwaikar A, Shirwaikar A. 2012. Formulation, characterization and optimization of hepatitis B surface antigen (HBsAg)-loaded chitosan microspheres for oral delivery. Pharm. Dev. Technol. 17:251-258.
35. Liu Z, Lv D, Liu S, Gong J, Wang D, Xiong M, Chen X, Xiang R, Tan X. 2013. Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice. PLoS One 8:e60190. doi:10.1371/journal.pone.0060190.
36. Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM. 2011. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin. Ther. Targets 15:1023-1035.
37. Pittet JF, Koh H, Fang X, Iles K, Christiaans S, Anjun N, Wagener BM, Park DW, Zmijewski JW, Matthay MA, Roux J. 2013. HMGB1 accelerates alveolar epithelial repair via an IL-1β- and αvβ6 integrin-dependent activation of TGF-β1. PLoS One 8:e63907. doi:10.1371/journal.pone.0063907.
38. Zhu H, Li J, Wang S, Liu K, Wang L, Huang L. 2013. Hmgb1-TLR4-IL-23-IL- 17A axis promote ischemia-reperfusion injury in a cardiac transplantation model. Transplantation 95:1448-1454.
39. Gougeon ML, Melki MT, Saidi H. 2012. HMGB1, an alarmin promoting HIV dissemination and latency in dendritic cells. Cell Death Differ. 19:96-106.
40. Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A, Raucci A, Sanvito F, Doglioni C, Nawroth PP, Bierhaus A, Bianchi ME, Rovere-Querini P, Del Maschio A. 2008. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J. Immunol. 180:2270-2275.
41. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA. 2004. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5:825-830.
42. Yang D, Postnikov YV, Li Y, Tewary P, de la Rosa G, Wei F, Klinman D, Gioannini T, Weiss JP, Furusawa T, Bustin M, Oppenheim JJ. 2012. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. J. Exp. Med. 209:157-171.
43. El Gazzar M. 2007. HMGB1 modulates inflammatory responses in LPS-activated macrophages. Inflamm. Res. 56:162-167.
44. Rottembourg D, Filippi CM, Bresson D, Ehrhardt K, Estes EA, Oldham JE, von Herrath MG. 2010. Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection. J. Immunol. 184:7100-7107.
45. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I. 2003. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48:971-981.
46. Wang H, Zhu S, Zhou R, Li W, Sama AE. 2008. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev. Mol. Med. 10:e32.
47. Cully M. 2013. Connective tissue diseases: HMGB1 helps elicit anti-dsDNA antibody production in SLE. Nat. Rev. Rheumatol. 9:321.
48. Robinson AP, Caldis MW, Harp CT, Goings GE, Miller SD. 2013. High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis. J. Autoimmun. 43:32-43.
49. Pullerits R, Jonsson IM, Verdrengh M, Bokarewa M, Andersson U, Erlandsson-Harris H, Tarkowski A. 2003. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48:1693-1700.
50. Muthumani G, Laddy DJ, Sundaram SG, Fagone P, Shedlock DJ, Kannan S, Wu L, Chung CW, Lankaraman KM, Burns J, Muthumani K, Weiner DB. 2009. Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology 128:e612-e620.
51. Gebhard JR, Perry CM, Harkins S, Lane T, Mena I, Asensio VC, Campbell IL, Whitton JL. 1998. Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am. J. Pathol. 153:417-428.
52. Opavsky MA, Penninger J, Aitken K, Wen WH, Dawood F, Mak T, Liu P. 1999. Susceptibility to myocarditis is dependent on the response of αβ T lymphocytes to coxsackieviral infection. Circ. Res. 85:551-558.
53. + T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 69:6720-6728.
54. Huber SA, Lodge PA. 1984. Coxsackievirus B-3 myocarditis in Balb/c mice: evidence for autoimmunity to myocyte antigens. Am. J. Pathol. 116:21-29.
55. Park JH, Kim DS, Cho YJ, Kim YJ, Jeong SY, Lee SM, Cho SJ, Yun CW, Jo I, Nam JH. 2009. Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis. Vaccine 27:1974-1983.
56. Williman J, Young S, Buchan G, Slobbe L, Wilson M, Pang P, Austyn J, Preston S, Baird M. 2008. DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza. Vaccine 26:5153-5158.